Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

544 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Hadziyannis SJ, et al. Among authors: marcellin p. Ann Intern Med. 2004 Mar 2;140(5):346-55. doi: 10.7326/0003-4819-140-5-200403020-00010. Ann Intern Med. 2004. PMID: 14996676 Clinical Trial.
Treatment of chronic hepatitis C with alpha-interferon.
Marcellin P. Marcellin P. Eur J Med. 1992 Jul-Aug;1(4):194-5. Eur J Med. 1992. PMID: 1341443 No abstract available.
Autoimmune chronic hepatitis exacerbated by alpha-interferon.
Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. Papo T, et al. Among authors: marcellin p. Ann Intern Med. 1992 Jan 1;116(1):51-3. doi: 10.7326/0003-4819-116-1-51. Ann Intern Med. 1992. PMID: 1727095 No abstract available.
[Treatment of chronic hepatitis C with interferon alpha].
Marcellin P, Benhamou JP. Marcellin P, et al. Gastroenterol Clin Biol. 1991;15(8-9):613-4. Gastroenterol Clin Biol. 1991. PMID: 1752372 Review. French. No abstract available.
[Interferon and chronic non-A, non-B hepatitis: status of the problem].
Marcellin P. Marcellin P. Acta Gastroenterol Belg. 1991 May-Aug;54(3-4):259-62. Acta Gastroenterol Belg. 1991. PMID: 1792840 French.
Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France.
Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP. Marcellin P, et al. Hepatology. 1991 Mar;13(3):393-7. Hepatology. 1991. PMID: 1900254 Clinical Trial.
Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy.
Marcellin P, Martinot-Peignoux M, Loriot MA, Giostra E, Boyer N, Thiers V, Benhamou JP. Marcellin P, et al. Ann Intern Med. 1990 Feb 1;112(3):227-8. doi: 10.7326/0003-4819-112-3-227. Ann Intern Med. 1990. PMID: 2297196 No abstract available.
Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.
Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP. Marcellin P, et al. Gastroenterology. 1995 Jul;109(1):156-65. doi: 10.1016/0016-5085(95)90281-3. Gastroenterology. 1995. PMID: 7540996 Clinical Trial.
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.
Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, et al. Martinot-Peignoux M, et al. Among authors: marcellin p. Hepatology. 1995 Oct;22(4 Pt 1):1050-6. Hepatology. 1995. PMID: 7557850 Clinical Trial.
Seventy-four percent of the patients had detectable serum HCV RNA (43%, 77% and 84%) in the three groups of patients with sustained response, relapse, and no response, respectively (P = .005). Mean serum HCV RNA level were 1.4 +/- 6 x 10(6), 4.8 +/- 6 x 10(6), and 3.9 +/- …
Seventy-four percent of the patients had detectable serum HCV RNA (43%, 77% and 84%) in the three groups of patients with sustained response …
544 results
Jump to page
Feedback